{
Aurobindo Pharma Limited

Companies

}
global bisoprolol fumarate market poised for significant growth through 2032
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
openPR.com
United States Dollar Merck & Co., Inc. Amgen Inc. Alkem Laboratories Limited Mylan Pharmaceuticals Inc. Aurobindo Pharma Limited Teva Pharmaceutical Industries Ltd Dr. Reddy's Laboratories Limited Glenmark Pharmaceuticals Limited CIPLA LTD Sandoz Group AG Pfizer Inc. Bayer AG Hikma Pharmaceuticals PLC AstraZeneca PLC Novartis AG Torrent Pharmaceuticals Limited Sanofi IND ROU BEL HUN DNK POL IDN SGP ARE BRA ZAF FRA THA MEX CZE GBR CHL AUT SAU SWE NOR NLD USA ARG MYS SVK CAN NZL LKA JPN DEU RUS KOR CHN VNM Nidhi Bhavsar Show more
Regulatory & Legal, Market Report
13:09 16.12.2024
YSRCP MPs Face Allegations of Fraud in Kakinada Port Stake Acquisition
Andhra Pradesh police have filed a case against YSRCP MP V Vijaysai Reddy and Y Vikranth Reddy for allegedly using coercive methods to fraudulently acquire stakes in Kakinada Seaports Ltd and Kakinada SEZ Ltd. The accusations include cheating, criminal intimidation, and conspiracy, with the stakes reportedly sold at a low price to Aurobindo Realty, now Auro Infra. Senior YSRCP leader Kakani Govardhan Reddy has dismissed the allegations as "political vendetta."
Moneycontrol
Aurobindo Pharma Limited IND V. Vijaysai Reddy Sarath Chandra Reddy Kakani Govardhan Reddy Y. V. Subba Reddy Vikranth Reddy Show more
Regulatory & Legal, News Article
07:08 05.12.2024
Global Generic Pharmaceuticals Market Sees Growth in Simple Generics and Biosimilars
India's "Pharmaceuticals Mission" aims to boost generic production, with simple generics leading the market due to cost-effectiveness and ease of manufacturing. Cardiovascular diseases drive demand, while small molecules dominate product types. Retail pharmacies remain the preferred distribution channel, and key players like Cipla and Teva are expanding their offerings.
GlobeNewswire News Room
United States Dollar Euro Fresenius Kabi AG Sanofi Aspen Pharmacare Holdings Ltd Sun Pharmaceuticals, Ltd. Aurobindo Pharma Limited Glenmark Pharmaceuticals Limited Pfizer Inc. Lupin Limited Dr. Reddy's Laboratories Limited Zydus Lifesciences Limited Teva Pharmaceuticals, Inc. Viatris Inc. Novartis AG Hikma Cipla Limited IND USA Show more
Healthcare, Market Report
16:30 04.12.2024
Allegations of Illegal Takeover of Kakinada Port Shares Against Jagan Mohan Reddy
Kakinada Seaports MD KV Rao has filed an FIR against former Andhra CM Jagan Mohan Reddy and YSRCP MP Vijay Sai Reddy for allegedly orchestrating the illegal takeover of Kakinada Port shares valued at thousands of crores. The complaint claims that 40% of the port was acquired for Rs 494 crore, significantly below its worth, and highlights accounting irregularities that deprived the government of Rs 1,000 crore in revenue.
Moneycontrol
Indian Rupee Aurobindo Pharma Limited GMR Group IND Vijay Sai Reddy YS Jagan Mohan Reddy Kv Rao Y. V. Subba Reddy Sarath Chandra Reddy Show more
Regulatory & Legal, News Article
13:37 04.12.2024
Aurobindo Pharma reports strong growth and sets target price at 1540
Aurobindo Pharma reported an 8% YoY increase in Q2FY25 consolidated revenue to Rs. 7,796 crore, driven by strong U.S. sales and significant growth in Europe and other markets. The company’s EBITDA rose 11.6% YoY to Rs. 1,566 crore, with an improved margin of 20.1%. Geojit Financial Services maintains a BUY rating with a target price of Rs. 1,540, reflecting a positive outlook for the company.
Moneycontrol
United States Dollar Euro Aurobindo Pharma Limited IND
Healthcare, Market Report
09:38 27.11.2024
Aurobindo Pharma rated buy with target price of 1591 by KR Choksey
KR Choksey has upgraded Aurobindo Pharma to a "BUY" rating with a target price of INR 1,591, following a stock price correction. Despite revenue meeting estimates, EBITDA and adjusted PAT fell short due to higher expenses and finance costs. The company is expected to achieve an 8.7% CAGR in revenue and a 17.7% CAGR in adjusted PAT from FY24 to FY26, supported by new product launches and improvements in its API business.
Moneycontrol
Indian Rupee Aurobindo Pharma Limited IND
Finance & Economy, Market Report
10:27 13.11.2024
Q2 earnings reports from major companies set to impact markets today
On November 9, at least 88 companies, including major players like Asian Paints, Divis Labs, and Aurobindo Pharma, are set to release their Q2 financial results for the July-September quarter. This earnings season, which began last month, is expected to significantly influence market trends and provide insights into India's economic landscape.
mint
Asian Paints Limited TVS Electronics Limited Aurobindo Pharma Limited Divi's Laboratories Limited Uttkarsh Small Finance Bank IND Divis Laboratories Asian Paints Aurobindo Pharma Show more
Finance & Economy, Market Report
02:06 09.11.2024
global small molecule injectable drugs market trends and regional insights 2021
The global small-molecule injectable drugs market reached $188.9 billion in 2021, with a projected growth rate of 8% CAGR, expected to hit $837.8 billion by 2030. North America leads the market with a 37% share, driven by increased R&D and product approvals, while Europe is anticipated to grow the fastest due to rising demand for minimally invasive procedures. Intravenous injections accounted for 30% of the market, highlighting their critical role in rapid drug administration.
Spherical Insights
United States Dollar Pfizer Inc. Novartis AG טבע תעשיות פרמצבטיות Ltd. Aurobindo Pharma Limited Merck & Co., Inc. FRA RUS GBR ITA ESP USA KOR SAU JPN MEX ARE ZAF BRA ARG CHN QAT AUS IND DEU CAN Merck & Co Teva Pharmaceutical Industries Ltd. Pfizer Inc. Novartis AG Inc. AstraZeneca Plc. Show more
Healthcare, Market Report
22:59 28.10.2024
pharma sector faces growth slowdown while domestic market thrives
Pharma giants are experiencing a slowdown in earnings growth, primarily due to their reliance on the US generics market and a lack of major drug launches. Companies like Cipla, Dr Reddy's, and Aurobindo Pharma face challenges from rising competition and impending patent expirations, while midcap firms focused on the domestic market continue to thrive without the same pressures.
Moneycontrol
United States Dollar Aurobindo Pharma Limited SBI Life Insurance Company Ltd. Cipla Limited DR Reddy'S Laboratoire Ltd. TVS Motor Company Limited HUL Lupin Limited IND Lupin Spiriva Cipla Dr Reddy's Aurobindo Pharma Show more
Healthcare, Market Report
05:31 25.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.